Astellas Pharmaceuticals Co. Ltd.
Astellas is No.2 in Japan and ranked number 20 worldwide with net sales of ¥ 1,348 Billion ($ 12 billion) in 2015.

It has a solid reputation as a leader in research based medicine as Astellas has research and development units at over 15 locations all around the world, including North America, Europe and Asia; Astellas is investing around ¥ 165 billion ($ 1.46 billion) in 2015.

The company’s R&D activities are focused on endocrinology, bone related disorders, and disease affecting the urogenital organs, central nervous system, circulatory system and digestive organs.

Astellas`s OMNIC ocas ‘‘tamsulosin” for example is being marketed in 65 countries around the world and is held No.1 position in its class in a lot of countries, including Saudi Arabia.
Astellas is committed to enforce the Urology and other pipelines with several new products which will be available in many regions through SAJA.